2024-03-19 01:46:56 ET
Summary
- FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone.
- TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs.
- As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.
...
Read the full article on Seeking Alpha
For further details see:
TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway